Aim is to develop antibodies that can detect protein fragments left by the cancer metastasing.

Strategic Diagnostics (SDI), University of Delaware, and the Helen F. Graham Cancer Center are coming together to develop assays to detect prostate cancer metastasis. SDI will leverage the center’s Genomic Antibody Technology™ during this project for biomarker discover.

The group will work to develop antibodies that detect the protein fragments left by cancer cells when they spread. They anticipate that a test using these antibodies will help determine the stage and severity of the cancer.

Cancer cells implanted in normal tissue of the body cause damage to surrounding proteins upon breaking away from the primary tumor, leaving behind protein molecule fragments, according to the collaborators. These fragments are indicators that the cancer has metastasized.

Previous articleEIP Becomes Stellar’s Partner in Turkey for Uracyst
Next articleResearchers Identify Three Genes that Better Measure Positive Response to CF Therapy